Benzinga··Vandana SinghBioMarin's Dwarfism Treatment Hits Milestone, Stock Jumps on Phase 3 Success
BioMarin's VOXZOGO met primary endpoint in hypochondroplasia study, showing significant growth improvement. Stock surged 8% on positive data.
BMRNFDA approvalPhase 3 study